{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T17:29:02Z","timestamp":1697304542617},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T00:00:00Z","timestamp":1255651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00292-009-1235-z","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T22:59:53Z","timestamp":1255561193000},"page":"283-289","source":"Crossref","is-referenced-by-count":2,"title":["Pseudomesotheliomat\u00f6ses Adenokarzinom der Lunge"],"prefix":"10.1007","volume":"31","author":[{"given":"K.","family":"Aumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00fcnter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Freudenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,16]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/jcp.55.9.662","volume":"55","author":"Abutaily","year":"2002","unstructured":"Abutaily AS, Addis BJ, Roche WR (2002) Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 55:662\u2013668","journal-title":"J Clin Pathol"},{"key":"1235_CR2","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1378\/chest.123.1_suppl.21S","volume":"123","author":"Alberg","year":"2003","unstructured":"Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123:21S\u201349S","journal-title":"Chest"},{"key":"1235_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00318606","volume":"271","author":"Andressen","year":"1993","unstructured":"Andressen C, Blumcke I, Celio MR (1993) Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 271:181\u2013208","journal-title":"Cell Tissue Res"},{"key":"1235_CR4","first-page":"445","volume":"9","author":"Bejarano","year":"1996","unstructured":"Bejarano PA, Baughman RP, Biddinger PW et al (1996) Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 9:445\u2013452","journal-title":"Mod Pathol"},{"key":"1235_CR5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/hupa.2001.24329","volume":"32","author":"Comin","year":"2001","unstructured":"Comin CE, Novelli L, Boddi V et al (2001) Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 32:529\u2013536","journal-title":"Hum Pathol"},{"key":"1235_CR6","unstructured":"ComprehensiveCancerCenterFreiburg CCCF (2006) Empfehlungen zur standardisierten Diagnostik, Therapie und Nachsorge: Lungenkarzinom"},{"key":"1235_CR7","unstructured":"DeutscheKrebsgesellschaft DKG (2008) Kurzgefasste interdisziplin\u00e4re Leitlinien 2008: Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen. Zuckerschwerdt, M\u00fcnchen"},{"key":"1235_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3835(97)00466-7","volume":"124","author":"Di","year":"1998","unstructured":"Di Loreto C, Puglisi F, Di Lauro V et al (1998) TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 124:73\u201378","journal-title":"Cancer Lett"},{"key":"1235_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","volume":"1","author":"Ellis","year":"2006","unstructured":"Ellis P, Davies AM, Evans WK et al (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1:591\u2013601","journal-title":"J Thorac Oncol"},{"key":"1235_CR10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1159\/000332172","volume":"42","author":"Harlamert","year":"1998","unstructured":"Harlamert HA, Mira J, Bejarano PA et al (1998) Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 42:1382\u20131388","journal-title":"Acta Cytol"},{"key":"1235_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ajcp\/65.2.159","volume":"65","author":"Harwood","year":"1976","unstructured":"Harwood TR, Gracey DR, Yokoo H (1976) Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer. Am J Clin Pathol 65:159\u2013167","journal-title":"Am J Clin Pathol"},{"key":"1235_CR12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/00313020400010955","volume":"36","author":"Henderson","year":"2004","unstructured":"Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J (2004) After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology 36:517\u2013550","journal-title":"Pathology"},{"key":"1235_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/hyb.1996.15.49","volume":"15","author":"Holzinger","year":"1996","unstructured":"Holzinger A, Dingle S, Bejarano PA et al (1996) Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 15:49\u201353","journal-title":"Hybridoma"},{"key":"1235_CR14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2559.2005.02331.x","volume":"48","author":"King","year":"2006","unstructured":"King JE, Thatcher N, Pickering CA, Hasleton PS (2006) Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 48:223\u2013232","journal-title":"Histopathology"},{"key":"1235_CR15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","volume":"57","author":"Kushitani","year":"2007","unstructured":"Kushitani K, Takeshima Y, Amatya VJ et al (2007) Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57:190\u2013199","journal-title":"Pathol Int"},{"key":"1235_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00022744-200206000-00001","volume":"10","author":"Lau","year":"2002","unstructured":"Lau SK, Luthringer DJ, Eisen RN (2002) Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 10:97\u2013102","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1235_CR17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.22477","volume":"109","author":"Mimura","year":"2007","unstructured":"Mimura T, Ito A, Sakuma T et al (2007) Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 109:933\u2013938","journal-title":"Cancer"},{"key":"1235_CR18","first-page":"335","volume":"51","author":"Mueller","year":"1997","unstructured":"Mueller KM (1997) Mesothelioma. Pathology\/pathogenesis\/mesothelioma register. Pneumologie 51:335\u2013344","journal-title":"Pneumologie"},{"key":"1235_CR19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1055\/s-2004-818505","volume":"58","author":"Mueller","year":"2004","unstructured":"Mueller KM (2004) Pleuromesothelioma \u2013 pathology and pathogenesis. Pneumologie 58:670\u2013679","journal-title":"Pneumologie"},{"key":"1235_CR20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0344-0338(98)80065-4","volume":"194","author":"Nagel","year":"1998","unstructured":"Nagel H, Hemmerlein B, Ruschenburg I et al (1998) The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract 194:759\u2013764","journal-title":"Pathol Res Pract"},{"key":"1235_CR21","first-page":"276","volume":"13","author":"Ordonez","year":"1989","unstructured":"Ordonez NG (1989) The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 13:276\u2013291","journal-title":"Am J Surg Pathol"},{"key":"1235_CR22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","volume":"27","author":"Ordonez","year":"2003","unstructured":"Ordonez NG (2003) The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27:1031\u20131051","journal-title":"Am J Surg Pathol"},{"key":"1235_CR23","first-page":"929","volume":"11","author":"Ordonez","year":"1998","unstructured":"Ordonez NG (1998) Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 11:929\u2013933","journal-title":"Mod Pathol"},{"key":"1235_CR24","first-page":"62","volume":"26","author":"Pomjanski","year":"2009","unstructured":"Pomjanski N, Onofre F, Buckstege B, Boecking A (2009) Multimodale Diagnose des Malignen Mesothelioms. Verh Dtsch Ges Pathol 26:62\u201363","journal-title":"Verh Dtsch Ges Pathol"},{"key":"1235_CR25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/dc.20556","volume":"34","author":"Saad","year":"2006","unstructured":"Saad RS, Lindner JL, Lin X et al (2006) The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 34:801\u2013806","journal-title":"Diagn Cytopathol"},{"key":"1235_CR26","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.07-1378","volume":"132","author":"Scott","year":"2007","unstructured":"Scott WJ, Howington J, Feigenberg S et al (2007) Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edn). Chest 132:234S\u2013242S","journal-title":"Chest"},{"key":"1235_CR27","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.123.1_suppl.188S","volume":"123","author":"Scott","year":"2003","unstructured":"Scott WJ, Howington J, Movsas B (2003) Treatment of stage II non-small cell lung cancer. Chest 123:188S\u2013201S","journal-title":"Chest"},{"key":"1235_CR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1092-9134(99)80042-2","volume":"3","author":"Shah","year":"1999","unstructured":"Shah IA, Salvatore JR, Kummet T et al (1999) Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases. Ann Diagn Pathol 3:148\u2013159","journal-title":"Ann Diagn Pathol"},{"key":"1235_CR29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/oem.51.12.804","volume":"51","author":"Spirtas","year":"1994","unstructured":"Spirtas R, Heineman EF, Bernstein L et al (1994) Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 51:804\u2013811","journal-title":"Occup Environ Med"},{"key":"1235_CR30","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/annonc\/mdn083","volume":"19","author":"Stahel","year":"2008","unstructured":"Stahel RA, Weder W, Felip E (2008) Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (Suppl 2):ii43\u201344","journal-title":"Ann Oncol"},{"key":"1235_CR31","first-page":"57","volume":"75","author":"Szczepulska-Wojcik","year":"2007","unstructured":"Szczepulska-Wojcik E, Langfort R, Roszkowski-Sliz K (2007) A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation. Pneumonol Alergol Pol 75:57\u201369","journal-title":"Pneumonol Alergol Pol"},{"key":"1235_CR32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jso.2930450204","volume":"45","author":"Tuttle","year":"1990","unstructured":"Tuttle SE, Lucas JG, Bucci DM et al (1990) Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies. J Surg Oncol 45:72\u201378","journal-title":"J Surg Oncol"},{"key":"1235_CR33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/1097-0142(197909)44:3<937::AID-CNCR2820440322>3.0.CO;2-K","volume":"44","author":"Wang","year":"1979","unstructured":"Wang NS, Huang SN, Gold P (1979) Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 44:937\u2013943","journal-title":"Cancer"},{"key":"1235_CR34","unstructured":"Wiethege T (2000) Differentialdiagnose b\u00f6sartiger Pleuratumoren. Immunhistochemische und molekularbiologische Untersuchungsbefunde. Inaugural-Disseration der Medizinischen Fakult\u00e4t Universit\u00e4t Essen"},{"key":"1235_CR35","unstructured":"Wittekind C, Meyer H-J, Bootz F (2002) UICC: TNM Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New York"},{"key":"1235_CR36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/modpathol.3800534","volume":"19","author":"Yaziji","year":"2006","unstructured":"Yaziji H, Battifora H, Barry TS et al (2006) Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19:514\u2013523","journal-title":"Mod Pathol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-009-1235-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-009-1235-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-009-1235-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T01:33:31Z","timestamp":1590197611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-009-1235-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s00292-009-1235-z","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,16]]}}}